Search

Study protocol of a multicentre, randomised, controlled trial evaluating the effectiveness of probiotic and peanut oral immunotherapy in inducing desensitisation or tolerance in children with peanut allergy compared with oral immunotherapy

Peanut allergy is the the most common cause of life-threatening food-induced anaphylaxis. There is currently no effective long-term treatment. There is a pressing need for definitive treatments that improve the quality of life and prevent fatalities.

Innate immune activation occurs in acute food protein–induced enterocolitis syndrome reactions

Food reactions in food protein–induced enterocolitis syndrome are predominantly underpinned by activation of the innate immune system

ASCIA Guideline: Infant Feeding for Food Allergy Prevention

The Australasian Society of Clinical Immunology and Allergy (ASCIA) Guideline: Infant Feeding for Food Allergy Prevention is an update of the 2016 ASCIA guideline. This updated guideline provides recommendations specifically in relation to infant feeding for food allergy prevention. 

The National Allergy Centre of Excellence–Addressing Australia's Allergy Burden

Australia has one of the highest rates of food allergy, anaphylaxis hospital admissions and anaphylaxis fatalities worldwide. These trends and sustained advocacy prompted a 2019 Parliamentary Inquiry into Allergies and Anaphylaxis. Among 250 submissions, the Centre for Food Allergy Research called for a national research-coordinating centre and comprehensive allergy research funding.

Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPE

The pivotal phase 3 EPITOPE trial, a 12-month, double-blind, placebo-controlled study of epicutaneous immunotherapy with the VIASKIN patch containing 250 μg of peanut protein (VP250), previously reported significant treatment response versus placebo in peanut-allergic toddlers aged 1 through 3 years.

Nuts For Babies Study: protocol for a randomised controlled trial in Australia

The predisposition to food allergy development and the induction of allergen-specific immune responses appears to be initiated early in infancy. Early exposure to food allergens, such as peanut and cashew nut, via human milk is likely important in initiating oral tolerance and reducing risk of food allergy development. This trial aims to determine if the risk of developing peanut and cashew nut allergy during infancy can be reduced by a high peanut and cashew nut maternal diet during lactation.

Developing a Standardised National Model of Care for Treatment of Peanut Allergy in Infants: The ADAPT Peanut Oral Immunotherapy Program

Peanut allergy is the most common food allergy in Australian school-aged children and is rarely outgrown. Access to oral immunotherapy (OIT), a disease-modifying treatment for food allergy, is limited in many regions of the world, including Australia.

Children with East Asian-Born Parents Have an Increased Risk of Allergy but May Not Have More Asthma in Early Childhood

Children of East Asian ancestry born in Australia have a higher burden of most allergic diseases in the first 6 years of life, whereas asthma may follow a different pattern

Protocol for Pertussis Immunisation and Food Allergy (PIFA): a case-control study of the association between pertussis vaccination in infancy

We therefore speculate that removal of wP from the vaccine schedule contributed to the observed rise in IgE-mediated food allergy among Australian infants

Effects of maternal dietary egg intake during early lactation on human milk ovalbumin concentration: A randomized controlled trial

Increased maternal egg ingestion is associated with increased breastmilk ovalbumin, and markers of immune tolerance in infants